Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer

NCT02864030 is registered in ClinicalTrials.gov with Oncologia Medica dell'Ospedale Fatebenefratelli as lead sponsor.

NCT NCT02864030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02864030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer
Lead sponsor
Oncologia Medica dell'Ospedale Fatebenefratelli
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2014
Completion date
December 31, 2020
Enrollment
200 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug event, drug toxicity, metastatic breast cancer, neurotoxicity, toxicity